Tough UK line on funding rare-disease drugs raises concern
Adding a funding cap for new therapies could make it harder for drugmakers to recoup development costs
London
A TOUGHER stance in the UK on funding expensive medicines for rare diseases is raising questions about the government's pledges to support a life-sciences industry that's already rattled by Brexit.
A proposal to introduce a cap on coverage of treatments within the state-run health system would have a significant impact on access to ultra-rare disease drugs, said Heidi Wagner, senior vice-president of global government affairs at Alexion Pharmaceuticals Inc. Last week, the US biotech company was denied support in England for Kanuma, a drug that's estimated to cost £492,000 (S$869,000) a year, because a key authority deemed it too expensive even after unspecified discounts.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
South Korea to slap fines on food suppliers for ‘shrinkflation’
Olam outbids Dreyfus’ sweetened deal for Australia’s Namoi, raises offer to A$0.66 per share
Live Nation’s revenue beats estimates as boom in concerts drive ticket sales
Jim Beam owner bets on canned vodka cocktails to double revenue
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Cordlife served letter of demand, notice of claim from customers